3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
83
Neoplasm Metastasis
9
Prostatic Neoplasms, Castration-Resistant
5
Neoplasms
3
Metastatic Castration-Resistant Prostate Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Urogenital Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Primary Myelofibrosis
2
Pancreatic Neoplasms
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Metastatic Castration-resistant Prostate Cancer (mCRPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Colorectal Neoplasms
2
Castration-resistant Prostate Cancer
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Thrombocytosis
1
Prostatic Diseases
1
Prostate Cancer Metastatic Disease
1
Prostate Adenocarcinoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Ovarian Neoplasms
1
Interventions
radium Ra 223 dichloride
2
pembrolizumab
2
enzalutamide
2
abiraterone
2
Injections
2
Abiraterone Acetate
2
niraparib
1
efineptakin alfa
1
darolutamide
1
capivasertib
1
cabazitaxel
1
apalutamide
1
Solutions
1
Radium-223
1
Prednisone
1
Pluvicto
1
PSMA-11
1
Lutetium-177
1
Lutetium
1
Docetaxel
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer (mCRPC)
×
abiraterone
×
Genitourinary
×
Clear all
NCT03903835
2025-04-09
ProBio
Karolinska Institutet
Phase 3
Recruiting
750 enrolled
NCT03896984
2021-12-29
PHENIX
Bayer
Completed
346 enrolled